December 9, 2021 12:44 PM EST

Ever optimistic despite concerns, BrainStorm teams with Catalent to prep for possible approval for ALS drug

Josh Sullivan

Catalent has entered a partnership with a cell therapy company that focuses on neurodegenerative diseases, taking on a tech transfer to manufacture treatments for ALS …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ever optimistic despite concerns, BrainStorm teams with Catalent to prep for possible approval for ALS drug

Josh Sullivan

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Versant unveils Light Horse with $62M and a partnership with Novartis

After lackluster 2024, biopharma industry prays stalled M&A will finally move into gear

Aiolos team reunites with $411M for new biotech with obesity drugs from China

Exclusive: First-of-its-kind infant DNA edit leads to apparent cure in disease that set back field 25 years ago

Cell therapy startup A2 Biotherapeutics nets $80M Series C

Leyden Labs gets $70M to test if nasal sprays can help protect against viruses

Ever op­ti­mistic de­spite con­cerns, Brain­Storm teams with Catal­ent to prep for pos­si­ble ap­proval for ALS drug

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Ever optimistic despite concerns, BrainStorm teams with Catalent to prep for possible approval for ALS drug